Compounds of the formula II: wherein R and R are independently H, F or CH； or R forms an ethynyl bond and R is H or C-C cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF, OMe or halo； R is C-C alkyl or C-Ccycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R is C-C cycloalkyl it may alternatively be gem subsituted with fluoro； R is methyl or fluoro； m is 0, 1 or 2； E is a bond, or thiazolyl, optionally substituted with methyl or fluoro； A is CH or N, A is CRR7 or NR, provided at least one Of A and A comprises N； R is H, C-C alkyl, C-C haloalkyl, C-C alkyl-O-C-C alkyl, or when A is C, R can also be C-C alkoxy or F； R is H, C-C alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
